Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics and keeping the price target at $6.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Zhu has given his Buy rating due to a combination of factors tied to Compass Therapeutics’ clinical progress and regulatory outlook. He views the COMPANION-002 results as materially strengthening the probability of approval, with management already preparing for a BLA filing and expecting clarity on the FDA path by around Labor Day, underpinned by a strongly positive progression-free survival signal despite a non-significant overall survival hazard ratio.
Zhu also highlights upcoming catalysts from the PD-1 x PD-L1 bispecific CTX-8371 and PD-1 x VEGF bispecific CTX-10726, including dose-escalation and early safety/efficacy readouts that could expand the company’s value proposition across multiple tumor types. Combined with a solid cash runway, ongoing Phase 2 planning for tovecimig, and active investigator-sponsored work in first-line biliary tract cancer, he sees a favorable risk-reward profile that supports maintaining a $6 price target and a Buy rating on CMPX shares.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.